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ABSTRACT 
Application of antiretrovirals (ARVs) in patients with Human Immunodeficiency Virus (HIV) infection 
has proven to reduce mortality rates and prolong life expectancy. On the other hand, the use of 
antiretroviral drugs has incited the emergence of HIVDR. The resistance is due to mutation at genes 
associated with drug resistance.  Nowadays, the determination of resistance markers mutations are based 
on HIV-1 subtype B. However, the majority of HIV in Indonesia, particularly in Bali are of subtype CRF01_AE. 
Genetic variation between HIV viruses has led to variations in subtypes; therefore, resistance markers  of 
subtype B could be  polymorphisms of non-B subtypes. This study aims to determine the number and types 
of the resistance markers mutations and polymorphisms that occur on the PR gene of HIV-1 subtype 
CRF01_AE of naïve and treatment failure patients in Bali. 
This is an observational cross-sectional analytical study, conducted at two VCT clinics in Denpasar, 
during the period of April 2010 until October 2011. Samples consist of 18 HIV patients with treatment 
failure and 30 naïve HIV patients. Mutations were evaluated using PCR, sequenced and aligned were 
carried out using MEGA4. Interpretations of the mutations were made based on the Stanford HIV database. 
Hypothesis tests used were Mann-Whitney because of abnormal distribution of data. Hypothesis was 
accepted if the significant level p<0.05. 
This study found that of the demographic data, only the predisposing factors of the two groups 
were significantly different (p<0.05). Two patients with treatment failure and 5 naïve patients were found 
to have L10LV/I mutations. Only one patient with treatment failure had the I54FI mutation. No major 
mutations were found among the two study groups. The number and types of minor mutations were not 
significantly different (p>0.05) between the naïve group and treatment failure group. M36I and H69K 
polymorphisms of the PR gene were found in all the study samples. 
In conclusion of this study, two types of major mutations were found, L10LV/I and I54FI. The number and 
types of the resistance markers mutations towards the protease inhibitor (PI) group were not significantly 
different between the two study groups. M36I, H69K mutations of the PR gene are markers of 
polymorphisms of HIV-1 subtype CRF01_AE. 
 
Keywords: HIV-1 subtype CRF01_AE, HIVDR, protease gene, antiretrovirals, resistance marker, mutation, 
polymorphism. 
 
INTRODUCTION 
The use of antiretrovirals (ARVs) in patients with 
Acquired Immune Deficiency Syndrome (AIDS) has 
proven to reduce mortality rates and prolong life 
expectancy. On the other hand, the effectiveness of 
ARVs is limited by the emergence of Human 
Immunodeficiency Virus drug resistance (HIVDR) 
strains. The nature of HIVDR strains is that these 
strains persist for as long as the life of a patient. These 
resistant strains reside as a minor species in the 
circulation or are only found in the genome of infected 
cells in a proviral state.1,2 HIVDR strains can be 
grouped  into   primary / transmitted  HIVDR   found 
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among patients that have never received ARVs (naïve 
patients) and acquired/secondary HIVDR, occurring 
when patients have received ARVs previously.1,3 
Spread of transmitted drug resistance (TDR) can be 
influenced by several factors, i.e. the type of drug 
used, duration of therapy, virus subtype, occurrence 
of coinfection and persistence of high risk behavior in 
the patient. Meanwhile, acquired HIVDR can occur 
because of lack of compliance of the patient in using 
ARVs and suboptimal therapy because of economic 
factors.1,2 Cases of HIVDR have spread to all over the 
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world, especially in regions where ARVs have been 
used for more than 4 years. 
Antiretrovirals have been used globally as a 
treatment for AIDS since 1995. In Indonesia, ARV were 
initially used in 2004. There are 811 HIV patients in 
Bali that are under treatment with ARVs.4 Even though 
many patients with HIV have received ARV therapy in 
Indonesia, at present there is no data on the 
prevalence of HIVDR in treatment failure cases. A 
study in Jakarta in 2009 found a prevalence of 
transmitted HIVDR among injecting drug users <5%.5 
HIVDR resistance mechanisms have mostly been 
acquired through studies of HIV-1 subtype B, which is 
commonly found in North America, West Europe, and 
Australia. However, the prevalence of HIV subtype B is 
only about 12% of all HIV in the world.6 Meanwhile, in 
Indonesia, 90.7% of people infected with HIV were 
infected by subtype CRF01_AE, which for practical 
reasons is grouped as non-B subtype.7 A large 
combination of HIV genome of only 104 bp with a large 
number of mutations and a high rate of replication has 
led to the emergence of variations in HIV subtypes.8 
Genetic variation between subtypes is 15-20%, 
whereas variations in nucleotides and amino acids of 
RT sequences and variations in proteases between 
subtypes are 10-12% and 5-6%, respectively.9 
This causes a problem in determining amino acid 
residues as markers of ARV resistance in non-B HIV 
subtypes. Several researchers have proven that some 
mutations that are related to drug resistance 
occurring in subtype B are normal mutations or 
normal variations (polymorphisms) in non-B 
subtypes.6,10,11 Polymorphisms occur differently in 
each subtype. A polymorphic position in one subtype 
is usually nonpolymorphic in another subtype. The 
opposite applies as well, as a nonpolymorphic position 
in one subtype is generally a polymorphic position in 
another subtype.3 Due to these reasons, studies on 
HIVDR in non-B HIV subtypes, such as CRF01_AE that 
is the most commonly found subtype in Indonesia, are 
still necessary. This study aims to determine the 
difference in number and types of mutations in 
markers of ARV resistance and polymorphisms of the 
protease gene (PR) amino acids in naïve and treatment 
failure patients with HIV subtype CRF01_AE in Bali. 
This study will be valuable in choosing therapy 
regimens in the treatment of patients with HIV. 
 
MATERIALS AND METHODS 
This study was performed using an observational 
cross sectional analytic study design. Samples for this 
study consisted of blood plasma of people with HIV 
infection who sought treatment at the  HIV clinic of 
Sanglah Hospital and Kerti Praja HIV clinic in Denpasar, 
during the period of April 2008 until May 2001, 
determined through a consecutive sampling 
technique. Inclusion criteria for the samples were 
patients with HIV who received antiretroviral therapy 
for the first time and patients declared as having 
treatment failure with a viral load of >750 copies/mL. 
RNA extraction and PCR were performed from April 
2010 until October 2011 at the Biomolecular 
Laboratory of the Faculty of Medicine, Udayana 
University. 
Before the process of RNA extraction, plasma 
was centrifuged at 21,000 g, 4°C for 90 minutes. As 
much as 200 μL of the sediment was collected for 
further processing. RNA of HIV-1 was extracted from 
the plasma sediment using QIAmp Viral RNA Mini Kit 
(Qiagen Corporation). Genetic material was amplified 
by RT-PCR and nested-PCR techniques, using a PCR 
thermocycle Biorad® machine. RT-PCR reactions used 
the Reverse Transcriptase-PCR Superscript™ III One-
Step RT-PCR System with Platinum® taq DNA 
Polymerase (Invitrogen®) reagent. Primers used for 
the first cycle were HIV-1F and HIV-1R. RT-PCR 
reaction for a single reaction consisted of RNA mix 
12.5 μL, HIV-1F primer 1.5 μL, HIV-1R primer 1.5μL, 
Taq polymerase 1 μL and template 8.5 μL. The cycle 
for RT-PCR reactions consisted of 55°C for 60 minutes 
for the RT reaction, 95°C for 2 minutes, 40x the 
following cycle: 95°C for 30 seconds 60°C for 30 
seconds 68°C for 2.5 minutes, and finally 68°C for 10 
minutes. Nested-PCR reactions used the Platinum® 
Taq DNA Polymerase High Fidelity (Invitrogen®) 
reagent with the primers HIVGRT-2F2 and HIVGRT-2R. 
Each single nested-PCR reaction consisted of 10x PCR 
buffer 2.27 μL, dNTP mix (10 mM) 0.45 μL, MgSO4 (50 
mM) 0.68 μL, HIV-2F2 primer 0.45 μL, HIV-2R primer 
0.45 μL, Taq polymerase 0.23 μL, H2O 19.56 μL and RT-
PCR product 0.91 μL. The cycle for nested-PCR 
reactions consisted of 94°C for 2 minutes, 30x the 
following cycle: 94°C for 30 seconds 57°C for 30 
seconds 68°C for 2 minutes, and lastly 68°C for 5 
minutes. Sequencing was performed at the Institute of 
Human Virology and Cancer Biology Universitas 
Indonesia (IHBCV-UI) in Jakarta. Sequencing reactions 
used 7 primers, i.e. primer A, b, C, D as forward 
primers and F, G, and H primers as reverse primers. 
Sequencing reactions used BigDye deoxy Terminator 
according to the procedure as instructed by the 
manufacturer, using the Applied Biosystems 310 
Sequencer machine. Subtypes and polymorphisms of 
the protease gene were compared to the standard 
subtype B based on the Stanford Drug Resistance 
Database (http://hivdb.stanford.edu). Meanwhile, to 
determine polymorphisms of subtype CRF01_AE, the 
standard strain CRF01_AE_CM240 was used. 
Normal distribution of the demographic variables 
data was tested using Shapiro-Wilk, because the 
number of samples was less than 50. For hypothesis 
testing, Mann-Whitney test was used if abnormal 
distribution of data was found. Chi square test was 
used to analyze differences between variables. 
Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS 16.0, Chicago, 
Illinois, USA) software. 
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RESULTS 
During this study, number of patients infected 
with HIV who fulfilled the inclusion criteria was 48 
patients. Demographic data showed that more males 
than females were investigated in both naïve group 
and treatment failure groups. There were 77.8% of 
male and 63.3% of female. Based on patients age, 
young adults (16-44 years old) were the majority in 
both groups. In the treatment failure group there 
were 16.7% children (age 5-15 years), while in the 
group of naïve patients there were no children. The 
duration from diagnosis of HIV infection until initiation 
of antiretroviral therapy was shorter among the group 
with treatment failure (mean 147 ± 216.8 days) 
compared to the naïve group (mean 324 ± 574 days). 
Meanwhile, the average duration from starting 
antiretroviral therapy until treatment failure occurred 
was 3 years (mean 1077 ± 461.7 days). The most 
common predisposing factor in both groups was 
heterosexual. Perinatal infection as a predisposing 
factor was only identified in the treatment failure 
group, while tattoos and heterosexual partners were 
only found in the naïve group (table 1). All patients 
with treatment failure received first line therapy that 
did not include antiretrovirals from the protease 
inhibitor (PI) group. Shapiro-Wilk normality testing of 
the variables of sex, age, duration and predisposing 
factors found an abnormal distribution. Mann-
Whitney testing of the demographic data of the 
patients found only the predisposing factors 
significantly different (p<0.05) between the two 
groups. Demographic analysis results of the patients 
are presented in Table 1. 
The purpose of PCR was to amplify the HIV pol 
gene. The result of nested-PCR consisted of PCR 
products of 1,800 bp that are detectable through 
electrophoresis as presented in Figure 1. 
 
 
Figure 1  
The product of nested PCR of the HIV pol gene. 
Column 1: marker; column 2: negative control; 
columns 3 and 4: sample. 
 
The PCR sequencing products depend immensely 
on the nested-PCR quality product. low quality, such 
as having a noisy background, short peak electrophero 
grams, or the presence of contaminations, it will be 
difficult to identify quasi-species in the samples. 
 
Table 1 
Demographic data of HIV patients of the naïve and 
treatment failure groups 
 
Variable 
Patients p 
Failure Naive 
Total 18 30 0.296 
• Male 14 (77.8%) 19 (63.3%)  
• Female 4 (22.2%) 11 (36.7%)  
Age (year)   0.56 
• 5-15 3 (16.7%) -  
• 16-44 15 (83.3%) 26 (86.7%)  
• 45-65 - 4 (13.3%)  
• Average 31.6 35.2  
• Range 5 - 48 27 - 50  
Duration (days)   0.163 
• Found HIV 
until starting 
ARV 
1 – 870 1 – 2,370  
• Mean 146.6 324.3  
• Starting ARV 
until 
treatment 
failure 
420 – 2,130 - 
 
 
• Mean 1,077.2 -  
Viral load  
(copies/mL) 
  0.354 
• Range 6,700 –
750,000 
2,345– 
750,000 
 
• Mean 213,595.72 261,315.83  
Predisposing 
factors: 
  0.018 
• Perinatal 
infection 
3 (16.7%) 
 
- 
 
 
• Tattoo+heter
osexual 
- 
 
1 (3.3%) 
 
 
• IVDU 5 (27.8%) 1 (3.3%)  
• IVDU+hetero 
sexual 
- 
 
1 (3.3%) 
 
 
• Heterosexual 10 (55.6%) 26 (86.7%)  
• Heterosexual 
partner 
- 1 (3.3%)  
IVDU = intravenous drug user 
 
In this study, to test antiretroviral resistance towards 
the PI group, all amino acid residues of the PR gene, 
consisting of 99 amino acid residues, were tested. In 
both the naïve and treatment failure groups, major 
mutations as markers of resistance were not found on 
the PR gene, but several minor mutations were 
identified. There were 2 amino acid residues as 
markers of resistant in the treatment failure group 
and only one amino acid residue in the naïve group. 
Changes in the amino acid residue type of the PR gene 
that occurred did not change the characteristic of that 
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amino acid residue (Table 2). There were 2 patients 
from the treatment failure group and 5 patients from 
the naïve group with the L10LV/I mutation. All of the 
patients were still sensitive to the PI group, as L10LV/I 
mutations were not found together with major 
mutations that are markers of PI resistance. Among 
the patients with treatment failure, one patient (code 
HNT 09) was found to have a mutation of codon 54. 
The mutation that occurred was the change of 
isoleusine (I) to phenylalanine (F) amino acid residue. 
The I54FI mutation is a polymorphism that is not 
associated with markers of resistance, therefore 
patient HNT 09 was still sensitive to all drugs of the PI 
group. 
 
Table 2 
Proportions of the number and types of mutations as 
markers of PI resistance (minor) among the 99 amino 
acid residues of the PR gene 
 
No Mutation 
Treatment 
failure Naïve p 
n=18 % n=30 % 
1 L10LV/I 2 11.1 5 16.7 0.696 
2 I54FI 1 5.6 0 0 0.375 
Number of 
changed AA 
2/99=2.0% 1/99=1.0% 1.000 
 
Notes: 99 = number of amino acids of the PR gene, AA= 
amino acid, NP.N= non polar neutral, Change in AA type for 
no.1: NP.N --> NP.N/NP.N, for no.2: NP.N --> NP.N/NP.N 
 
Statistical analysis of minor mutations of the PR 
gene and markers of NNRTI resistance of the RT gene 
found p>0.05. Therefore, it can be concluded that 
there was no significant difference between the 
numbers of mutations that are markers of resistance 
among the two groups (Table 3). 
 
Table 3 
Comparison of  mutations that are markers of 
resistance of the PR gene 
 
Gene Mutation Treatment failure Naïve p 
PR Major 0 0 - 
 Minor 2% 1% 1.00 
 
PR genes of the naïve group had an average of 3.92 
polymorphisms, compared to the standard 
AE_CM240. There was one patient whose PR gene did 
not have polymorphisms compared to the standard 
(patient code HT17). Only on position 57 did the 
amino acids of naïve patients have a 72% difference 
compared to the standard, i.e. lysine (K) of the 
standard became arginine (R) in the patient. The other 
amino acid residues of naïve patients were <25% 
different from the standard (6 amino acids) (image 3). 
The average of polymorphisms of the PR gene in the 
treatment failure group was 3.5. This result was 
smaller than the result of the naïve group (Figure 3).  
         Analysis of sequencing results in order to 
determine resistance patterns towards antiretrovirals 
used the Stanford HIV database. Analysis results 
identify mutations that are markers of resistance and 
other mutations with the standard HIV-1 subtype B for 
comparison. 
 
 1111223334 4566777889 99 
 0256095791 5723027291 37 
#Standard
_AE_CM240 
LTIGKDDNPK KKILKIVVMT IL 
#HNT_02_n I.V....... .R........ .. = 3 
#HNT_05_n ?.....?... .R.......? .. = 4 
#HR_06_n .........R .R........ .. = 2 
#HT_03_n ??.?R...S. .R........ .. = 6 
#HT_10_n ...ER..... .?....I... L. = 5 
#HT_11n ...ER....? RRVP?.I... L.= 10 
#HT_17_n   .......... .......... .. = 0 
#HT_42_n   .......... .R........ .. = 1 
#HT_48_n ....R.E... .R..?..... L. = 5 
#HNT_08_n ...ER.E... .R.?RT..IA .. = 9 
 
A.   Polymorphisms of the PR gene of 10 study samples 
in the naïve patient group 
Note: amino acids are stated by single letter codes. Dots 
(.) represent amino acids that at that position are the 
same as the standard. Question marks (?) represent 
amino acids that at that position have more than one 
type of amino acid. n= naïve. 
 1111111233 5667778999 
 0234569057 7130272137 
Standard_AE
_CM240 
LTVKIGLKDN KQLKIVVTIL 
#H01_gt .......... ..P....... = 1 
#HNT_06_gt .?I?...... R.....I.L. = 6 
#HNT_10gt .......?E. R..R...... = 4 
#HR_08_gt .....A.... R......... = 2 
#HR_14_gt .......R.. R....I.... = 3 
#HR_21gt ?AI.V..... R.PR...... = 7 
#HT_02gt I....E.R.. R........I = 5 
#HT_53_gt ..I....... R.P.....L. = 4 
#HT59_gt ....V..... R........F = 3 
#hnt_04_gt ..I......D R.?.....L. = 5 
 
B. Polymorphisms of the PR gene of 10 study samples 
in the treatment failure group 
Note: amino acids are stated by single letter codes. Dots (.) 
represent amino acids that at that position are the same 
as the standard. Question marks (?) represent amino acids 
that at that position have more than one type of amino 
acid. gt = “gagal terapi” (treatment failure). 
 
Figure 4 
Polymorphisms of the PR gene of 10 study samples in 
the treatment failure and naïve groups 
 
Other mutations that are not markers of resistance 
are polymorphisms of HIV-1 subtype non-B. A 
mutation is considered a marker of non-B subtypes if 
polymorphic mutations are found in both patient 
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groups with a prevalence of >90%. These mutations 
can be used as markers for HIV-1 subtype CRF01_AE if 
the prevalence in both study groups reaches 100%. 
Therefore, amino acid residues that can be used as 
markers for subtype CRF01_AE in this study are M36I, 
H69K of the PR gene (Table 4). 
DISCUSSION 
In this study, two groups of patients were 
studied, i.e. naïve and treatment failure HIV patients. 
In the naïve group, the average time from diagnosis of 
HIV infection until initiation of antiretroviral therapy 
was 11 weeks. The reason for this is that these 
patients were diagnosed as infected with HIV for the 
first time and sought treatment when they were 
category B or C of the HIV severity classification. 
 
Table 4 
Polymorphisms of the PR gene in the treatment failure 
and naïve groups compared to the standard HIV-1 
subtype B 
Gene Mutation 
Treatment 
Failure Naïve 
PR  n=18 % n=30 % 
 E35D 16 88.9 26 86.7 
 M36I 18 100 30 100 
 R41K 18 100 28 93.3 
 H69K 18 100 30 100 
 L89M 18 100 28 93.3 
 
Therefore, these patients are often called chronic 
naïve HIV patients. In the treatment failure group, the 
time from diagnosis of HIV infection until receiving 
antiretrovirals was shorter, with an average of 5 
weeks. The majority of patients in the treatment 
failure group came in the AIDS stage or category C and 
required immediate antiretroviral therapy. The 
average duration from the initiation of therapy until 
treatment failure occurred was 3 years. This result is in 
accordance with a study in Cameroon, in which 
mutations that are markers of antiretroviral resistance 
are found in patients that are exposed to 
antiretrovirals for more than 14 months. Meanwhile, 
mutations that are markers of resistance are not 
found in patients that have used antiretrovirals for 9 
months.12 
Results of statistical testing of the demographic 
data of both study groups found only the predisposing 
factors variable to be significantly different (p<0.05) 
between the two groups. In the treatment failure 
group, more IVDU patients were found, who generally 
have the tendency of being noncompliant. Kozal et al. 
(2009) also reported that HIVDR patients have a 
tendency to maintain their high risk behavior. 
Compliance of patients in the treatment failure group 
is expected to be lower than the naïve group.13 
Mutations that are markers of PI resistance were 
not found in both of the groups. Minor mutations 
were found in the treatment failure and naïve groups, 
16.6% and 16.7%, respectively. The reason being that 
none of the patients had used antiretrovirals of the PI 
group before. Meanwhile, minor mutations can occur 
as a result of normal mutations during the replication 
process of HIV. Major mutations (D30N, M64I, G48V, 
I50N, V82A/F/T, I84V, L90M) and minor mutations 
(L101I/R/V, K20M/R, L24I, V32I, L33F, M36I, M46I/L, 
I47V, I54L/M/V, L63P, A71V/T, G73S, V77I, V82I, 
N88D) associated with the PR gene can be identified 
based on the International AIDS Society-USA (Johnson 
et al., 2008). In this study, the most common minor 
mutation was the L10LV/I and only one I54FI mutation 
was found in the treatment failure group. The 
L101/F/V/R mutation is a polymorphic mutation, but is 
associated with resistance to the entire PI group if 
found together with other mutations.14-17 Mutations of 
codon 54 where isoleusine is replaced by Leusine/L or 
Val/V or Thr/T (I54L/V/T mutation) increases 
resistance towards the entire PI group if found 
together with other mutations.14,17,18  A study in Rio de 
Janeiro involving 49 naïve HIV patients did not find 
major mutations in any of the patients. However, 
minor mutations were found in 85%, particularly L63P 
mutations that were found in 54%.20 Natural 
polymorphisms of non-B subtypes that are commonly 
found as mutations marking PI resistance in subtype B 
in Africa are L10I/V, K20I/R, M36I, L63P and V77I.21 
The result of the PR sequence analysis in this 
study found several mutations that were always 
present in both of the patient groups. Mutations that 
were always found on the PR gene of the treatment 
failure group and in >90% of the naïve group are M36I, 
R41K, L89M and H69K, while E35D was only found in 
>85% of both groups. Santos and Soares (2010) 
reported several mutations of the non-B subtype that 
are associated with decreased sensitivity towards the 
PI group, but are not mutations marking resistance to 
the PI group in subtype B.22 These mutations are called 
genetic signatures. Mutations that are always present 
in one subtype but do not affect sensitivity to drugs 
are called polymorphisms. These mutations are I13V, 
K20I, M36I, H69K, V82I and I93L.22 A study by Ode 
(2007) found that the samples of subtype CRF01_AE 
used contained polymorphisms (K20R, E35D, I93L) and 
genetic signatures (M36I, R41K, H69K, L89M).23 
Sensitivity to atazanavir (ATV), indinavir (IDV), 
nelfinavir (NFV) and tipranavir (TPV) are associated 
with the M36I mutation. The H69K mutation is only 
associated with atazanavir.22 Other studies have not 
reported any influence of the R41K and L89M 
mutations on certain types of PIs.23 All of the genetic 
signatures identified by Ode were also found in this 
study, but only the polymorphism E35D was found in 
this study. 
 
CONCLUSION 
Two types of minor mutations were found, i.e. 
L10LV/I and I54FI. The I54FI mutation was only found 
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in one treatment failure patient, and in none of the 
naïve patients. Major mutations were not found; 
therefore, no patients were resistant to the PI group. 
The number and types of mutations between the 
naïve and treatment failure group were not different 
significantly (p>0.05). M36I, H69K polymorphisms of 
the PR gene can be used as a marker of subtype 
CRF01_AE. 
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